McKesson Corporation Third Quarter Fiscal 2026 Earnings Call February 4, 2026 1 © 2026 McKesson Corporation. All rights reserved. Cautionary Statements Cautionary Statements In an effort to provide additional and useful information regarding the Company's financial results and other financial information as determined by generally accepted accounting principles (GAAP), certain materials in this presentation include non-GAAP information. The Company believes the presentation of non-GAAP measures provides use ...

Exhibit 99.1 McKESSON CORPORATION REPORTS FISCAL 2026 THIRD QUARTER RESULTS AND RAISES FULL YEAR ADJUSTED EPS GUIDANCE IRVING, Texas, February 4, 2026 - McKesson Corporation (NYSE:MCK) today announced results for the third quarter ended December 31, 2025. Third Quarter Highlights: Fiscal 2026 Full Year Outlook: "McKesson delivered another strong quarter, extending the momentum we've built across the enterprise and demonstrating the impact of our disciplined execution," said Brian Tyler, chief executive offi ...

Key Takeaways MCK is expected to post Q3 fiscal 2026 sales of $105.54B, reflecting 10.8% year-over-year growth.MCK's EPS is projected to climb 15.9% to $9.31, with consensus estimates stable over the past month.MCK's results are likely to benefit from oncology strength, GLP-1 volume growth and efficiency gains.McKesson Corporation (MCK) is scheduled to report third-quarter fiscal 2026 results on Feb. 4, after market close.The Zacks Consensus Estimate for sales is pegged at $105.54 billion, implying 10.8% ye ...

Core Viewpoint - McKesson Corporation is positioned as a leading healthcare services and information technology company, with strong anticipated earnings growth and revenue increase for the upcoming quarter [1][2]. Financial Performance - Analysts expect McKesson to report earnings per share (EPS) of $9.31, reflecting a 15.9% increase from the previous year [2][6]. - Revenue is projected to reach $105.54 billion, marking a 10.8% rise from the same quarter last year [2][6]. - The consensus EPS estimate has remained unchanged over the past 30 days, indicating strong analyst confidence in the company's performance [3][6]. Valuation Metrics - The price-to-earnings (P/E) ratio is 26.03, suggesting that investors are willing to pay a premium for the company's earnings [4][6]. - The price-to-sales ratio is 0.27 and the enterprise value to sales ratio is 0.29, indicating a reasonable valuation relative to sales [4]. - The enterprise value to operating cash flow ratio is 16.16, showcasing the company's cash flow generation capabilities [4]. Capital Structure and Liquidity - The earnings yield stands at 3.84%, providing insight into the return on investment [5][6]. - A negative debt-to-equity ratio of -5.63 indicates a unique capital structure that may require further analysis [5][6]. - The current ratio is 0.88, suggesting potential liquidity considerations as it is below the ideal level of 1.0 [5].

Group 1 - McKesson Corporation is highlighted as a stock that typically performs well during earnings reports, with a history of stock price increases following such announcements [1] - The company distributes pharmaceutical drugs and medical-surgical supplies, and also offers healthcare technology and business services [2] - Despite a significant top-line miss in the last quarter, McKesson reported a strong earnings beat and provided a higher-than-expected full-year earnings forecast [2] - The stock has gained 22% since the mention in the episode aired on May 14, 2025 [3] Group 2 - The healthcare sector is currently facing scrutiny from the president, particularly targeting drug middlemen and distributors [1] - McKesson, along with other drug distributors, is noted for being strong performers over the long term, despite the perception of being vulnerable to market fluctuations [2]

Industry Overview - The Zacks Medical - Dental Supplies industry is expected to maintain upward momentum in 2026 due to innovation, an aging population, and normalized orders post-COVID-19 [1] - The global medical supplies industry is projected to reach $163.5 billion by 2027, growing at a CAGR of 3.4% from 2022 to 2027 [4] Technological Advancements - Continued adoption of digital services and AI-enabled tools is anticipated to enhance patient experience and reduce administrative burdens for physicians [2] - Innovations such as CAD/CAM systems, 3D imaging, and AI diagnostics are expected to improve treatment efficacy and broaden product use [8] Market Trends - The industry is shifting towards higher-margin specialty areas like oncology and urology, with precision health and theranostics emerging as significant trends [3] - There is a growing emphasis on preventive care and minimally invasive procedures, which is expanding market segments for dental consumables [9] Regional Growth Drivers - Emerging markets, particularly in Asia-Pacific, are benefiting from increased healthcare expenditure and improved access to care, contributing to faster growth rates [10] Economic Factors - Strong healthcare infrastructure and higher disposable income in developed regions support the adoption of advanced dental products [11] Challenges - U.S. tariffs have raised costs on essential imported dental supplies, leading to increased prices and supply-chain disruptions [12] - The industry is responding by shifting supply chains towards domestic production to mitigate tariff exposure [13] Company Performance - The industry has outperformed its sector with a collective gain of 6.6% over the past year, compared to the Zacks Medical sector's rise of 1.9% [16] - The industry is currently trading at a forward P/E of 17.67X, lower than the S&P 500's 22.81X [19] Company Insights - West Pharmaceutical is expected to maintain growth momentum in 2026, driven by demand for high-value products and operational improvements [21][22] - McKesson anticipates revenue growth of 11-15% in fiscal 2026, supported by strong demand in specialty distribution [30] - Cardinal Health expects revenues from its Pharmaceutical segment to grow 15-17% year-over-year, with challenges from competitive pricing pressures [35] - Align Technology is positioned for growth in 2026 due to restructuring actions and technological innovations, with a projected revenue increase of 3.7% [42]

Company Performance - McKesson (MCK) closed at $821.84, reflecting a -2.22% change from the previous day, underperforming the S&P 500's daily loss of 2.06% [1] - Over the past month, McKesson's shares have increased by 2.7%, while the Medical sector has decreased by 0.88% and the S&P 500 has gained 1.63% [1] Upcoming Earnings - McKesson's earnings report is scheduled for February 4, 2026, with expected earnings of $9.19 per share, indicating a year-over-year growth of 14.45% [2] - The consensus estimate for revenue is $105.66 billion, representing a 10.88% increase compared to the same quarter last year [2] Fiscal Year Estimates - For the entire fiscal year, the Zacks Consensus Estimates predict earnings of $38.61 per share and revenue of $408.23 billion, reflecting changes of +16.82% and +13.7% respectively from the previous year [3] Analyst Estimates - Recent modifications to analyst estimates for McKesson indicate the dynamic nature of near-term business trends, with upward revisions suggesting analysts' positive outlook on the company's operations [4] Zacks Rank - McKesson currently holds a Zacks Rank of 2 (Buy), with the Zacks Rank system showing a strong track record of success, particularly for 1 stocks which have delivered an average annual return of +25% since 1988 [6] Valuation Metrics - McKesson has a Forward P/E ratio of 21.77, which is a premium compared to the industry average Forward P/E of 18.28 [7] - The company's PEG ratio is 1.38, while the Medical - Dental Supplies industry average PEG ratio is 1.97 [7] Industry Overview - The Medical - Dental Supplies industry, part of the Medical sector, has a Zacks Industry Rank of 54, placing it in the top 23% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Company Overview - McKesson Corporation (NYSE:MCK) is one of the largest healthcare products and services providers in America [2] - The company's shares have gained 42% over the past year but have decreased by 5% since late November [2] Analyst Ratings - Deutsche Bank raised McKesson's share price target to $904 from $861 and maintained a Buy rating, noting that the company's plans to exit its surgical business could be dilutive but may also enhance share price performance [2] - TD Cowen also maintained a Buy rating with a price target of $1,000, expressing optimism about McKesson's growth potential and ability to meet long-term targets [2] Market Context - Jim Cramer commented on McKesson in relation to President Trump's views on the healthcare industry, suggesting that potential pricing reforms could negatively impact the company [2] - Despite these concerns, McKesson's stock continues to reach 52-week highs, indicating resilience against political pressures [2]

Company Overview - McKesson Corporation (NYSE:MCK) is a leading healthcare services and information technology company, providing pharmaceuticals and medical supplies in the United States and internationally, playing a crucial role in the healthcare supply chain [1] Stock Performance - On January 14, 2026, a new price target for McKesson was set at $968, suggesting a potential increase of about 16.16% from the current trading price of approximately $833.36 [2] - The stock's current price is $833.07, reflecting a slight increase of 1.10% or $9.09, with trading between $820.13 and $834.72 [2] Institutional Investments - GWN Securities Inc. acquired a new stake in McKesson, purchasing 3,570 shares valued at approximately $2.76 million during the third quarter, indicating growing interest in the stock [3] - Solstein Capital LLC significantly increased its position in McKesson by 171.4% in the second quarter, now holding 38 shares valued at $28,000, with other institutional investors also making new investments [4] Market Capitalization and Trading Activity - McKesson's market capitalization stands at approximately $104.13 billion, highlighting its significant presence in the healthcare sector [5] - The stock has reached a high of $895.58 and a low of $570.51 over the past year, with a trading volume of 56,584 shares on the New York Stock Exchange, indicating active investor interest [5]

Core Insights - McKesson is a diversified health care services leader serving various constituents in the health care sector, including pharmacies, providers, biopharma manufacturers, payers, and patients [4] Group 1: Company Overview - McKesson distributes 33% of pharmaceuticals across North America daily, showcasing its significant market presence [4] - The company has established connections with over 1 million providers and 50,000 pharmacies, indicating a vast operational network [4] - McKesson's USON MSO is projected to touch over 20% of all cancer patients in the U.S. this year, highlighting its impact in oncology care [4]